|
1
|
Pernot S, Terme M, Voron T, Colussi O,
Marcheteau E, Tartour E and Taieb J: Colorectal cancer and
immunity: What we know and perspectives. World J Gastroenterol.
20:3738–3750. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ikemoto T, Shimada M, Ishikawa D, Teraoku
H, Yoshikawa M, Yamada S, Takasu C, Saito Y, Morine Y and Imura S:
The clinical impact of CD4+ CD49b+ regulatory
T cells addition to FOXp3+ regulatory T cells in cancer
patients' immunity. J Am Coll Surg. 221:e222015. View Article : Google Scholar
|
|
3
|
Zhong Z, Sanchez-Lopez E and Karin M:
Autophagy, inflammation, and immunity: A troika governing cancer
and its treatment. Cell. 166:288–298. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chang WJ, Du Y, Zhao X, Ma LY and Cao GW:
Inflammation-related factors predicting prognosis of gastric
cancer. World J Gastroenterol. 20:4586–4596. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shalapour S and Karin M: Immunity,
inflammation, and cancer: An eternal fight between good and evil. J
Clin Invest. 125:3347–3355. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tran E, Turcotte S, Gros A, Robbins PF, Lu
YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS,
et al: Cancer immunotherapy based on mutation-specific
CD4+ T cells in a patient with epithelial cancer.
Science. 344:641–645. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen DS and Mellman I: Oncology meets
immunology: The cancer-immunity cycle. Immunity. 39:1–10. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yan J, Smyth MJ and Teng MWL: Interleukin
(IL)-12 and IL-23 and their conflicting roles in cancer. Cold
Spring Harb Perspect Biol. Jul 17–2017.(Epub ahead of print).
|
|
9
|
Stanilov N, Miteva L, Deliysky T, Jovchev
J and Stanilova S: Advanced colorectal cancer is associated with
enhanced IL-23 and IL-10 serum levels. Lab Med. 41:159–163. 2010.
View Article : Google Scholar
|
|
10
|
Coffelt SB, Kersten K, Doornebal CW,
Weiden J, Vrijland K, Hau CS, Verstegen NJM, Ciampricotti M,
Hawinkels LJAC, Jonkers J, et al: IL-17-producing γδ T cells and
neutrophils conspire to promote breast cancer metastasis. Nature.
522:345–348. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lin Q, Xue L, Tian T, Zhang B, Guo L, Lin
G, Chen Z, Fan K and Gu X: Prognostic value of serum IL-17 and VEGF
levels in small cell lung cancer. Int J Biol Markers. 30:e359–e363.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fabre J, Giustiniani J, Garbar C,
Antonicelli F, Merrouche Y, Bensussan A, Bagot M and Al-Dacak R:
Targeting the tumor microenvironment: The protumor effects of IL-17
related to cancer type. Int J Mol Sci. 17:E14332016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Iwakura Y and Ishigame H: The IL-23/IL-17
axis in inflammation. J Clin Invest. 116:1218–1222. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liang SC, Tan XY, Luxenberg DP, Karim R,
Dunussi-Joannopoulos K, Collins M and Fouser LA: Interleukin
(IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively
enhance expression of antimicrobial peptides. J Exp Med.
203:2271–2279. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sica A, Allavena P and Mantovani A: Cancer
related inflammation: The macrophage connection. Cancer Lett.
267:204–215. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Grivennikov S, Karin E, Terzic J, Mucida
D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H,
Eckmann L, et al: IL-6 and Stat3 are required for survival of
intestinal epithelial cells and development of colitis-associated
cancer. Cancer Cell. 15:103–113. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yamaguchi Y, Fujio K, Shoda H, Okamoto A,
Tsuno NH, Takahashi K and Yamamoto K: IL-17B and IL-17C are
associated with TNF-alpha production and contribute to the
exacerbation of inflammatory arthritis. J Immunol. 179:7128–7136.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Punt S, Fleuren GJ, Kritikou E, Lubberts
E, Trimbos JB, Jordanova ES and Gorter A: Angels and demons: Th17
cells represent a beneficial response, while neutrophil IL-17 is
associated with poor prognosis in squamous cervical cancer.
OncoImmunology. 4:e9845392015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Straus DS: TNFα and IL-17 cooperatively
stimulate glucose metabolism and growth factor production in human
colorectal cancer cells. Mol Cancer. 12:782013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bagheri N, Azadegan-Dehkordi F, Shirzad H,
Rafieian-Kopaei M, Rahimian G and Razavi A: The biological
functions of IL-17 in different clinical expressions of
Helicobacter pylori-infection. Microb Pathog. 81:33–38.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li L and Boussiotis VA: The role of
IL-17-producing Foxp3+CD4+ T cells in
inflammatory bowel disease and colon cancer. Clin Immunol.
148:246–253. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Helbling M, Lukesch A, Haimovici A,
Karamitopoulou E, Berger MD, Hädrich M, Mallaev M, Schnüriger B,
Koelzer VH, Dawson H, et al: Investigation of IL-23 (p19, p40) and
IL-23R identifies nuclear expression of IL-23 p19 as a favorable
prognostic factor in colorectal cancer: A retrospective multicenter
study of 675 patients. Oncotarget. 5:4671–4682. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen G, Liang Y, Guan X, Chen H, Liu Q,
Lin B, Chen C, Huang M, Chen J, Wu W, et al: Circulating low IL-23:
IL-35 cytokine ratio promotes progression associated with poor
prognosisin breast cancer. Am J Transl Res. 8:2255–2264.
2016.PubMed/NCBI
|
